地塞米松(Dexamethasone) - 药物靶点：GR_在研适应症：术后炎症，黄斑水肿，非感染性后葡萄膜炎_专利_临床

概要

基本信息

简介地塞米松是一种具有糖皮质激素受体 (GR) 激动作用的小分子药物。 GR 广泛分布于各种细胞类型，负责无数生理反应，包括免疫和炎症反应。地塞米松与 GR 结合，通过基因表达和蛋白质合成发挥激动作用，从而降低机体炎症反应，降低免疫系统活动。地塞米松已证明可以治疗多种疾病，包括但不限于光化性唇炎、轻链 (AL) 淀粉样变性、眼部炎症、黄斑水肿和过敏反应。早在 1958 年 10 月 30 日，FDA 就批准了地塞米松。此外，英国国家卫生服务局和美国国立卫生研究院推荐地塞米松用于需要机械通气或补充氧气（无通气）的COVID-19患者。

药物类型

小分子化药

别名

CMIO-DEX、Decadron Phosphate、Dexamethasone Intravitreal Implant

+ [50]

靶点

GR

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

肿瘤免疫系统疾病感染+ [13]

在研适应症

术后炎症黄斑水肿非感染性后葡萄膜炎+ [75]

非在研适应症

急性外耳炎急性中耳炎淋巴母细胞淋巴瘤+ [74]

原研机构

在研机构

+ [36]

非在研机构

Otonomy, Inc.

Eli Lilly & Co.Allergan UC

+ [33]

权益机构

AcuCort ABAffaMed Therapeutics (HK) Ltd.

EyePoint, Inc.

+ [14]

最高研发阶段批准上市

首次获批日期

美国 (1958-10-30),

过敏反应内分泌系统疾病眼部疾病+ [7]

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C22H29FO5

InChIKeyUREBDLICKHMUKA-CXSFZGCWSA-N

CAS号50-02-2

关联

2,179

项与地塞米松相关的临床试验

NCT07600151

/ Not yet recruiting临床1/2期IIT

A Clinical Phase I/II, Multicenter, Open-label, National Study Evaluating Quintuplet Treat-ment With ISaTuximab, Bortezomib, Lenalidomide and Dexamethasone Plus Etentamig (Etenta-Isa-VRd) in Primary DiagnOsed High-Risk Multiple Myeloma Patients

This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.

开始日期2026-12-01

申办/合作机构

Universitätsklinikum Hamburg-Eppendorf

[+2]

NCT07837674

/ Not yet recruitingN/AIIT

Impact of Intravenous Dexamethasone on the Duration of Motor and Sensory Block Following Spinal Anesthesia With Chloroprocaine

The purpose of this study is to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.

开始日期2026-11-01

申办/合作机构-

NCT07609706

/ Not yet recruiting临床1期

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment

The goal of the clinical trial is to collect safety data and information on how the body processes BVd in people with multiple myeloma (MM) who have moderate liver problems, compared with similar participants who have normal liver function. It also compares how liver problems affect the body's handling of belantamab mafodotin and uses the results to help set safe and appropriate dosing guidance for MM participants with moderate liver problems.

开始日期2026-10-23

申办/合作机构

GSK Plc

100 项与地塞米松相关的临床结果

登录后查看更多信息

100 项与地塞米松相关的转化医学

登录后查看更多信息

100 项与地塞米松相关的专利（医药）

登录后查看更多信息

67,514

项与地塞米松相关的文献（医药）

2027-01-01·JOURNAL OF ETHNOPHARMACOLOGY

Xiaoqinglong decoction suppresses M1 macrophage polarization in COPD via the MET/AKT/HK2 axis: An integrated multi-omics analysis

Article

作者: Gu, Jingzhe ; Qu, Haonan ; Chu, Yuanyuan ; Chen, Meng ; Zhang, Di ; Li, Yujing ; Zhang, Dongmei ; Zhang, Yao ; Ge, Fei ; Zhang, Furong

ETHNOPHARMACOLOGICAL RELEVANCE:

Xiaoqinglong Decoction (XQLD), a classic herbal formula for respiratory diseases, is clinically effective against chronic obstructive pulmonary disease (COPD). However, whether its anti-inflammatory effects involve modulation of macrophage immunometabolism remains unknown.

AIM OF THE STUDY:

This study investigated whether XQLD suppresses M1 macrophage polarization in COPD by modulating glycolysis-related pathways.

MATERIALS AND METHODS:

COPD was induced in rats by alternate intratracheal instillation of papain (Papa) and lipopolysaccharide (LPS). After modeling, the rats received XQLD at high, medium, and low doses, while a separate group received dexamethasone as the positive control. Therapeutic effects on pulmonary function and lung pathology were evaluated, along with M1 polarization by immunofluorescence and other assays. Core pathways were identified through transcriptomic-metabolomic integration. In vitro, XQLD-containing serum was used to treat THP-1-derived M1 macrophages, and M1 polarization, glycolytic indicators, and MET/AKT/HK2 pathway proteins were assessed following treatment with 2-DG, HK2 overexpression, or HGF.

RESULTS:

XQLD dose-dependently improved pulmonary function and lung pathology, and reduced M1 infiltration. Multi-omics identified MET and HK as central nodes; XQLD reversed aberrant MET/AKT/HK2 expression in vivo. In vitro, XQLD-containing serum inhibited M1 polarization, glycolytic flux, and HGF-induced MET/AKT/HK2 signaling, with its effects partially reversed by HK2 overexpression.

CONCLUSION:

XQLD attenuates M1 macrophage-driven airway inflammation by normalizing the MET/AKT/HK2 signaling-metabolic axis and suppressing, at least in part, HK2-dependent glycolysis. These findings provide a novel immunometabolic mechanism for the traditional anti-inflammatory efficacy of XQLD in COPD.

2027-01-01·JOURNAL OF ETHNOPHARMACOLOGY

Hanchuan Zupa Granules attenuate host inflammatory and redox dysregulation in a pretreatment model of Pseudomonas aeruginosa-triggered acute lung injury

Article

作者: Feng, Jian-Ting ; Zhang, Bo ; Chen, Hong-Mei ; Dong, Shi ; Ji, Xin-Ye ; Liu, Pei

ETHNOPHARMACOLOGICAL RELEVANCE:

Acute infectious lung injury involves excessive innate inflammation, oxidative stress, and epithelial barrier damage. Hanchuan Zupa Granules (HCZP), a Uyghur patent medicine, are traditionally used for cold-type Nazla characterized by cough, dyspnea, and viscous sputum.

AIM OF THE STUDY:

To evaluate the pretreatment-associated protective effects of HCZP on host injury responses in a Pseudomonas aeruginosa-triggered acute lung injury model and to explore related pathway-associated readouts and traceable constituents.

MATERIALS AND METHODS:

Kunming mice received HCZP pretreatment (0.72-2.88 g/kg, gavage) before P. aeruginosa challenge; dexamethasone served as a pharmacological comparator. BALF protein leakage, lung histology, and pathway-associated readouts were assessed at 24 h. LPS-stressed A549 cells treated with HCZP-medicated serum were used as a controlled epithelial support model. Public scRNA-seq data (GSE276682), LC-MS profiling, docking, and constituent validation were integrated as systematic pathway-associated and constituent-oriented analyses.

RESULTS:

HCZP pretreatment reduced BALF protein leakage, lung structural damage, and mucus hypersecretion, accompanied by lower IL-1β/TNF-α expression, moderated TLR4/NF-κB and PI3K/Akt signaling, enhanced Nrf2-associated antioxidant responses, and reduced apoptosis-related readouts. HCZP-medicated serum lowered ROS, restored GSH, and reduced PI-positive A549 cell death. Public scRNA-seq analysis highlighted neutrophil/myeloid remodeling in an LPS context. LC-MS prioritized liquiritin and apigenin as candidate traceable constituents with supportive in vitro epithelial activity.

CONCLUSIONS:

HCZP attenuated inflammation- and redox-related lung injury in P. aeruginosa-challenged mice, while liquiritin and apigenin were prioritized as candidate traceable constituents with supportive in vitro epithelial activity.

2026-12-31·Adipocyte

Wt1 facilitates visceral beige fat formation to combat abdominal obesity

Article

作者: He, Lin-Fei ; Chen, Jun-Ling ; Yang, Zhi-Chun ; Liao, Zhi-Mei

Visceral fat has weaker beige adipogenesis than subcutaneous fat with unclear mechanisms. The Wilms tumour gene (Wt1), a visceral adipocyte marker, is highly expressed in visceral adipose tissue (VAT) and visceral adipose-derived stem cells (vADSCs). In our present study, we found its protein levels in VAT decreased under high-fat diet or dexamethasone treatment, but rised in cold exposure or β3-adrenergic receptor agonist treatment, and positively correlate with uncoupling protein-1 (UCP1). Wt1 knockdown in vADSCs elevated PR domain containing 16 (PRDM16) and UCP1 mRNA but reduced their protein levels, alongside decreased ubiquitin-conjugating enzyme 9 (UBC9). Knockdown of UBC9 did not affect the mRNA levels of Wt1, PRDM16 or UCP1, but significantly reduced PRDM16 and UCP1 protein levels. Glucocorticoids including hydrocortisone, methylprednisolone and dexamethasone (Dex) dose-dependently suppress Wt1, UCP1, Alpha-enolase (ENO1) and Pyruvate kinase muscle isozyme M2 (PKM2) levels, which could be reversed by Wt1 overexpression. These findings explore the effects of Wt1 on beige remodelling of visceral adipose which might be related to the up-regulation of UBC9, and provide clues for treating abdominal obesity caused either by HFD or by glucocorticoids in a non-sympathetic-dependent manner.

4,935

项与地塞米松相关的新闻（医药）

2026-10-09

·GlobeNewswire-Health Care

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to fifteen newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of October 5, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 70,150 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 22,900 shares of Ocular’s common stock. The stock option awards have an exercise price of $7.25 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares for each award vesting on the one-year anniversary of the applicable recipient’s commencement of employment, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & MediaOcular Therapeutix, Inc.Bill SlatteryVice President, Investor Relationsbslattery@ocutx.com

临床3期临床2期

2026-10-09

·冰洲石生物

骨髓瘤新药获批不到两个月，III期PFS从20个月延长至42个月

一款今年8月刚获得美国FDA加速批准的多发性骨髓瘤新药，不到两个月又交出了一份重要的III期临床结果。 10月8日，百时美施贵宝公布，旗下Zenbexus（iberdomide）联合达雷妥尤单抗和地塞米松，在EXCALIBER-RRMM III期研究中达到无进展生存期（PFS）主要终点。新方案的中位PFS达到42个月，对照治疗组为20个月，相差22个月。疾病进展或死亡的相对风险降低51%。这组数据值得关注，但它并不代表患者能够多活22个月。PFS衡量的是疾病得到控制、不发生进展或死亡的时间，而不是总体生存时间。更特别的是，这款药物已经在8月13日获得FDA加速批准。当时支持批准的主要证据是微小残留病灶（MRD）阴性完全缓解率，而非成熟的PFS结果。如今，同一项III期研究的另一项共同主要终点也取得阳性结果，让这款已经上市的新药获得了更直接的临床获益证据。复发之后，骨髓瘤还有多少治疗空间？多发性骨髓瘤是一种起源于浆细胞的血液系统恶性肿瘤。正常浆细胞负责产生抗体，帮助人体抵御感染。但当浆细胞发生恶性增殖后，异常细胞会不断在骨髓中积累，影响正常造血，还可能引起骨骼损伤、贫血、肾功能异常和反复感染。近年来，多发性骨髓瘤的治疗已经取得明显进展。蛋白酶体抑制剂、免疫调节药物、抗CD38单克隆抗体，以及CAR-T细胞治疗和双特异性抗体，逐渐改变了患者的治疗选择。但这种疾病仍然难以彻底治愈。部分患者在初次治疗后能够获得较长时间的疾病控制，但随着时间推移，仍然可能出现复发。此时，医生需要根据患者此前使用过的药物、治疗反应以及身体状态，重新选择治疗方案。此次EXCALIBER-RRMM研究主要针对已经接受过一至两线治疗、随后出现疾病进展的成年患者。研究排除了对既往抗CD38单抗或硼替佐米治疗产生难治性的患者，因此结果不能直接推广到所有多线治疗失败的骨髓瘤患者。百时美施贵宝希望通过一种新一代口服药物，与现有抗CD38抗体联合使用，让复发患者获得更长时间的疾病控制。42个月对20个月，III期结果公布 EXCALIBER-RRMM是一项随机、开放标签III期临床研究，采用两阶段设计，包括前期剂量优化和后续疗效验证。研究整体共随机纳入939名患者，但不同主要终点采用了不同的预设分析人群。此次公布的PFS确认性分析涉及800名患者，两组各400人。试验组接受iberdomide、达雷妥尤单抗和地塞米松联合治疗，简称ZDd方案。对照组接受达雷妥尤单抗、硼替佐米和地塞米松，简称DVd方案。根据10月8日公布的顶线结果，ZDd组的中位PFS为42个月，DVd组为20个月。风险比（HR）为0.49，P值小于0.000001，达到统计学显著性要求。这意味着，与对照方案相比，ZDd使疾病进展或死亡的相对风险估计降低了51%。对于一种容易复发、需要长期治疗的血液肿瘤，延长疾病控制时间具有实际意义。患者如果能够更长时间不发生进展，就可能推迟更换后续治疗方案的时间。但中位PFS并不是患者的平均生存时间。 42个月意味着，根据研究估计，试验组约有一半患者在这一时间点前发生疾病进展或死亡事件，另一半患者尚未发生。此次公告还有一个容易引起疑问的数字：研究中位随访时间为23个月。为什么中位随访只有23个月，却能得到42个月的中位PFS？原因在于，患者并不是同一天入组，实际接受观察的时间也不同。部分较早入组的患者可能已经接受更长时间的随访。研究人员可以利用不同患者的随访时间和疾病进展事件，通过Kaplan-Meier方法估计无进展生存曲线及其中位值。因此，中位随访23个月与估计的中位PFS达到42个月，并不必然矛盾。不过，目前百时美施贵宝公布的仍是顶线结果，尚未提供完整的生存曲线、后期在险人数及相关置信区间。这些数据将帮助外界进一步判断42个月这一估计值的精确程度，以及较长随访时间下的疗效是否稳定。更重要的是，此次PFS阳性尚不能证明患者的总体生存时间已经延长。总生存期（OS）仍需后续随访确认。8月获批时，FDA依据的还不是PFS Zenbexus于2026年8月13日获得美国FDA加速批准。获批方案为iberdomide联合达雷妥尤单抗皮下注射制剂及地塞米松，用于此前至少接受过一线治疗，且既往治疗包含蛋白酶体抑制剂和免疫调节药物的成年多发性骨髓瘤患者。当时支持批准的关键证据，来自EXCALIBER-RRMM研究的另一项共同主要终点：MRD阴性完全缓解率。 MRD即微小残留病灶。患者接受治疗后，即使常规检查已经达到完全缓解，体内仍可能残留极少量恶性浆细胞。MRD检测通过更高灵敏度的方法，寻找这些常规检查难以发现的肿瘤细胞。如果患者达到完全缓解，并且MRD检测也呈阴性，说明治疗反应达到更深的程度。在多发性骨髓瘤中，MRD阴性通常与更好的长期疾病控制结果相关，因此逐渐成为重要的临床研究指标。此前公布的EXCALIBER-RRMM数据中，420名患者进入主要MRD疗效分析。 ZDd组的MRD阴性完全缓解率为41.1%，对照DVd组为20.7%，两组相差20.4个百分点，差异具有统计学显著性。这意味着，新方案能够让更多患者获得更深入的治疗反应。但MRD阴性完全缓解率属于替代终点。它能够反映残留肿瘤细胞的清除程度，却不能直接代替长期临床获益。 FDA加速批准制度允许针对严重疾病，在替代终点等证据显示潜在临床获益时提前批准药物，但上市后仍需要进一步验证实际获益。这也是为什么Zenbexus已经获批，企业仍然需要继续完成PFS等关键终点分析。从8月的MRD结果，到10月的PFS阳性，EXCALIBER-RRMM提供了两类不同的证据。前者显示，ZDd能够使更多患者达到深度缓解；后者则显示，这种联合治疗能够使患者获得更长时间的疾病控制。两者之间形成了更完整的疗效证据链。不过，10月公布PFS阳性，并不代表FDA已经自动将Zenbexus的加速批准转为传统批准。后续监管决定仍需依据完整资料作出。把硼替佐米换成iberdomide，治疗发生了什么变化？此次III期研究并不是使用三款全新的药物。两组患者都接受达雷妥尤单抗和地塞米松，区别主要在第三种药物。对照DVd方案使用硼替佐米，这是一种已经广泛用于多发性骨髓瘤治疗的蛋白酶体抑制剂。新方案ZDd则使用iberdomide。 Iberdomide属于新一代cereblon E3连接酶调节剂，也称为CELMoD。它通过与cereblon结合，促进IKZF1和IKZF3等参与骨髓瘤细胞生存及免疫调控的蛋白降解，从而抑制骨髓瘤细胞，并影响相关免疫反应。这与来那度胺、泊马度胺等传统免疫调节药物具有机制上的联系，但iberdomide对cereblon及下游蛋白降解的调节具有自身特点。因此，它并不是完全从零开始开发的一种全新治疗原理，而是在已有免疫调节药物基础上进一步发展的蛋白降解类药物。此次EXCALIBER-RRMM的结果，为这一新一代CELMoD药物在多发性骨髓瘤中的临床应用提供了重要证据。 Iberdomide采用口服给药，获批剂量为每28天周期的第1至21天每日1 mg。但需要注意，ZDd并不是完全口服的治疗方案。患者仍然需要接受达雷妥尤单抗皮下注射和地塞米松治疗。此外，不能仅凭两组第三种药物不同，就把全部疗效差异简单归结为iberdomide单药优于硼替佐米。 EXCALIBER-RRMM直接证明的是ZDd这一完整联合方案，相对于DVd方案的治疗优势。疾病控制时间延长，感染和血液学毒性也在增加 42个月对20个月的PFS结果十分突出，但安全性同样需要关注。在此前发表于《柳叶刀·肿瘤学》的研究分析中，ZDd组92%的患者发生3级或4级不良事件，对照DVd组为70%。其中，中性粒细胞减少是新方案较为突出的风险。 ZDd组3级或4级中性粒细胞减少发生率约为84%，对照组约为11%。两组3级或4级感染发生率分别约为39%和22%，严重不良事件发生率分别约为58%和41%。此外，新方案组的致死性感染发生率约为2%，对照组约为1.5%。这些数据说明，更明显的治疗获益伴随着需要认真管理的毒性风险。中性粒细胞是人体抵御细菌和部分真菌感染的重要免疫细胞。当其数量明显降低时，患者发生严重感染的风险可能升高。多发性骨髓瘤患者本身就可能存在免疫功能异常，再加上长期治疗带来的影响，感染预防、血常规监测和及时处理不良反应十分重要。不过，两种方案的安全性并不是所有方面都朝同一方向变化。此前研究中，ZDd组外周感觉神经病变的发生率低于DVd组。这可能与对照方案使用硼替佐米有关。因此，评价两种治疗方案的安全性，不能只看某一种不良事件的发生率。除骨髓抑制和感染外，Zenbexus的美国处方信息还包含胚胎-胎儿毒性，以及严重静脉和动脉血栓栓塞风险的黑框警告。在此前204名接受新方案的安全性分析患者中，静脉血栓栓塞事件发生率为6.4%，动脉血栓栓塞事件发生率为3.4%。其中包括深静脉血栓、肺栓塞、心肌梗死和卒中等风险。这些数据来自已经公开的较早期安全性分析，并不是10月8日800名患者PFS确认性分析的最终安全性结果。百时美施贵宝表示，此次新分析的安全性总体与既往研究结果一致，详细数据将在后续学术会议上披露。对于Zenbexus而言，接下来最重要的仍是两方面。一方面，需要确认PFS优势在更长期随访中能否持续，以及是否最终转化为总生存期改善。另一方面，也需要进一步明确，在获得更长疾病控制时间的同时，如何管理血液学毒性、感染和血栓风险。百时美施贵宝计划在第68届美国血液学会年会上展示更完整的研究结果。 8月13日，Zenbexus凭借MRD阴性完全缓解率获得加速批准。10月8日，新公布的PFS结果又为这一治疗方案提供了重要的临床证据。对于复发或难治性多发性骨髓瘤患者，中位PFS从20个月延长至42个月是一项明确的研究进展。但在长期治疗中，疗效能够维持多久、毒性是否可以接受，以及患者能否获得最终的生存获益，仍然是决定这款药物临床价值的重要问题。本文仅作生物医药行业信息分享与讨论，不构成医疗或投资建议。未经允许，不得转载。欢迎 “点赞” “在看” ，让更多人看到

2026-10-09

·BioSpace

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 9, 2026

BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to fifteen newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of October 5, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 70,150 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 22,900 shares of Ocular’s common stock. The stock option awards have an exercise price of $7.25 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares for each award vesting on the one-year anniversary of the applicable recipient’s commencement of employment, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ® , an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations bslattery@ocutx.com

临床3期临床2期

100 项与地塞米松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00292	地塞米松	D07AB19 H02AB02 D10AA03	DB01234

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
黄斑水肿	美国	AbbVie, Inc.	2026-03-11
非感染性后葡萄膜炎	美国	AbbVie, Inc.	2026-03-11
免疫球蛋白轻链淀粉样变性	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2021-08-25
免疫球蛋白轻链淀粉样变性	日本	Sandoz KK	2021-08-25
眼部炎症	美国	Ocular Therapeutix, Inc.	2018-11-30
眼科外科手术	美国	Ocular Therapeutix, Inc.	2018-11-30
术后炎症	美国	EyePoint, Inc.	2018-02-09
术后炎症	美国	EyePoint Pharmaceuticals US, Inc.	2018-02-09
糖尿病性黄斑水肿	欧盟	AbbVie Deutschland GmbH & Co. KG	2010-07-26
糖尿病性黄斑水肿	冰岛	AbbVie Deutschland GmbH & Co. KG	2010-07-26
糖尿病性黄斑水肿	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2010-07-26
糖尿病性黄斑水肿	挪威	AbbVie Deutschland GmbH & Co. KG	2010-07-26
视网膜静脉阻塞相关黄斑水肿	欧盟	AbbVie Deutschland GmbH & Co. KG	2010-07-26
视网膜静脉阻塞相关黄斑水肿	冰岛	AbbVie Deutschland GmbH & Co. KG	2010-07-26
视网膜静脉阻塞相关黄斑水肿	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2010-07-26
视网膜静脉阻塞相关黄斑水肿	挪威	AbbVie Deutschland GmbH & Co. KG	2010-07-26
后葡萄膜炎	欧盟	AbbVie Deutschland GmbH & Co. KG	2010-07-26
后葡萄膜炎	冰岛	AbbVie Deutschland GmbH & Co. KG	2010-07-26
后葡萄膜炎	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2010-07-26
后葡萄膜炎	挪威	AbbVie Deutschland GmbH & Co. KG	2010-07-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
术后疼痛	申请上市	新加坡	上海蔼睦医疗科技有限公司	2024-02-19
疼痛	临床3期	中国	Ocular Therapeutix, Inc.	2023-08-17
疼痛	临床3期	中国	上海蔼睦医疗科技有限公司	2023-08-17
葡萄膜炎	临床3期	中国	欧康维视生物医药（上海）有限公司	2022-08-22
视网膜炎	临床3期	美国	AbbVie, Inc.	2021-10-12
青光眼	临床3期	-	Ocular Therapeutix, Inc.	2020-11-01
开角型青光眼	临床3期	-	Ocular Therapeutix, Inc.	2020-11-01
浆细胞瘤	临床3期	美国	Millennium Pharmaceuticals, Inc.	2016-11-29
梅尼埃病	临床3期	美国	Otonomy, Inc.	2015-10-27
眼睛疼痛	临床3期	-	Ocular Therapeutix, Inc.	2014-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01745588 (CTgov)	临床2期	难治性多发性骨髓瘤	23	stem cell+Pomalidomide+Clarithromycin (Clarithromycin + Pomalidomide + Dexamethasone + Stem Cell)	築夢醖廠鏇廠齋鏇淵觸 = 膚蓋膚範餘齋製廠艱鑰簾憲鹽窪衊廠鹹簾艱構 (襯顧築鹹艱顧鑰遞鬱襯, 繭齋淵製衊窪製窪簾鹹 ~ 鹹選遞網淵鏇簾簾衊齋) 更多	-	2026-09-25
				Pomalidomide+Clarithromycin+Dexamethasone (Clarithromycin + Pomalidomide + Dexamethasone Alone)	築夢醖廠鏇廠齋鏇淵觸 = 艱憲窪餘廠壓網願繭網簾憲鹽窪衊廠鹹簾艱構 (襯顧築鹹艱顧鑰遞鬱襯, 壓簾鏇壓觸築構蓋蓋構 ~ 艱觸鹽顧夢鬱窪鬱夢構) 更多
NCT04484623 (DREAMM-8, IMS2026)	临床3期	多发性骨髓瘤二线	159	Belantamab Mafodotin, Pomalidomide, and Dexamethasone (BPd)	獵廠憲齋範繭構齋顧憲(窪鏇獵獵壓壓醖遞選膚) = 範簾範壓憲鏇遞築鹹膚醖蓋壓網醖壓構壓齋夢 (糧夢製夢夢醖淵壓範築 ) 更多	积极	2026-09-23
				Pomalidomide, Bortezomib, and Dexamethasone (PVd)	獵廠憲齋範繭構齋顧憲(窪鏇獵獵壓壓醖遞選膚) = 窪簾鹽鹽糧選鹽衊壓窪醖蓋壓網醖壓構壓齋夢 (糧夢製夢夢醖淵壓範築 ) 更多
NCT04484623 (DREAMM-8, IMS2026)	临床3期	复发性多发性骨髓瘤	302	Belantamab Mafodotin+Pomalidomide+Dexamethasone	衊觸糧構獵範齋積鹹鏇(衊鏇壓膚襯願鏇獵醖鏇) = 觸鏇壓獵製壓膚糧製選範夢糧繭糧積構鏇鑰構 (範鬱壓艱範鏇網構築齋 )	积极	2026-09-23
				Pomalidomide+Bortezomib+Dexamethasone	衊觸糧構獵範齋積鹹鏇(衊鏇壓膚襯願鏇獵醖鏇) = 範艱願壓鏇膚選淵壓網範夢糧繭糧積構鏇鑰構 (範鬱壓艱範鏇網構築齋 )
NCT05590923 (CTgov)	临床4期	化疗引起的恶心和呕吐 \| 恶心 \| 呕吐	23	DEX (Dexamethasone) (DEX (Dexamethasone))	範選觸夢鏇繭廠齋齋壓 = 遞鹽廠遞鏇衊憲選衊鬱觸積製齋遞齋簾願觸遞 (膚顧蓋積製鏇構艱獵膚, 憲窪壓鏇鬱夢夢獵簾糧 ~ 製獵餘蓋鹽餘鏇襯積襯) 更多	-	2026-09-02
				OLA (Olanzapine) (OLA (Olanzapine))	範選觸夢鏇繭廠齋齋壓 = 衊獵壓網鬱廠遞淵淵襯觸積製齋遞齋簾願觸遞 (膚顧蓋積製鏇構艱獵膚, 鹹鬱醖鹹鹽壓築壓艱鏇 ~ 醖醖蓋艱鬱觸膚願鬱鏇) 更多
NCT05018091 (CTgov)	临床4期	-	438	Dexamethasone 4mg (Group 1)	範襯襯窪選鏇襯艱鑰襯(糧積繭憲醖顧憲簾遞衊) = 膚積築艱遞壓鑰餘衊襯襯膚鑰鑰構齋繭夢憲築 (願觸築獵顧糧廠遞廠選, 168.9) 更多	-	2026-08-03
				Dexamethasone 8 Mg/mL Injectable Suspension (Group 2)	範襯襯窪選鏇襯艱鑰襯(糧積繭憲醖顧憲簾遞衊) = 餘構鑰淵夢繭鬱襯糧製襯膚鑰鑰構齋繭夢憲築 (願觸築獵顧糧廠遞廠選, 122.3) 更多
NCT06128369 (OPTIMIZE-2, CTgov)	临床3期	眼睛疼痛 \| 眼部炎症 \| 黄斑水肿 ... 更多	117	OCS-01 (OCS-01)	觸製鑰範醖鬱積壓築憲 = 製憲構醖構餘襯鬱簾夢鹹衊夢齋壓廠襯鹹蓋遞 (膚觸窪夢蓋鏇築築艱膚, 獵簾製齋獵選築鑰製衊 ~ 構簾範糧窪襯鏇鏇餘鹽) 更多	-	2026-07-30
				Vehicle (Vehicle)	觸製鑰範醖鬱積壓築憲 = 選鏇蓋簾糧膚齋範製鏇鹹衊夢齋壓廠襯鹹蓋遞 (膚觸窪夢蓋鏇築築艱膚, 鏇窪艱鬱鹹簾範積憲鏇 ~ 網襯簾糧憲製築簾遞衊) 更多
NCT02516423 (CTgov)	临床3期	浆细胞瘤	11	Lenalidomide+ixazomib+zoledronic acid+dexamethasone (Ixazomib + Lenalidomide + Dexamethasone + Zoledronic Acid)	築餘製窪憲膚壓醖顧壓 = 衊憲夢壓襯鹹獵餘範窪廠餘憲醖壓鹽襯築鑰繭 (鹽築繭膚壓壓網簾夢蓋, 繭鬱淵選艱鹽艱蓋齋襯 ~ 淵廠築網糧構膚糧顧鹹) 更多	-	2026-06-30
				zoledronic acid (Zoledronic Acid)	築餘製窪憲膚壓醖顧壓 = 鹹糧鹹觸襯壓築觸範艱廠餘憲醖壓鹽襯築鑰繭 (鹽築繭膚壓壓網簾夢蓋, 膚觸選蓋構構衊鹽糧夢 ~ 選網願鬱遞鹹醖蓋觸願) 更多
NCT07150104 (CTgov)	临床1/2期	多发性骨髓瘤	14	Mafodotin+Nirogacestat+Pomalidomide+Dexamethasone+Belantamab	鹹築鏇鹹膚窪膚構壓願 = 獵遞願醖簾積壓蓋鬱鬱廠顧廠壓廠襯願淵憲襯 (蓋淵襯衊鏇簾糧壓範窪, 築顧網選衊醖壓觸廠繭 ~ 憲築膚選夢繭構繭鑰構) 更多	-	2026-06-25
NCT07150091 (CTgov)	临床1/2期	多发性骨髓瘤	20	Mafodotin+Lenalidomide+Nirogacestat+Dexamethasone+Belantamab (0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone)	鏇選繭鏇壓觸觸艱願衊 = 網鬱構積網糧築選廠繭網蓋觸廠願鏇觸簾簾鹽 (鑰築鹹願窪鹹網構觸夢, 淵願壓壓簾範製觸鹽襯 ~ 廠廠簾膚選淵膚範蓋築) 更多	-	2026-06-16
				Mafodotin+Lenalidomide+Nirogacestat+Dexamethasone+Belantamab (1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone)	鏇選繭鏇壓觸觸艱願衊 = 憲淵願夢顧繭鑰鹽窪醖網蓋觸廠願鏇觸簾簾鹽 (鑰築鹹願窪鹹網構觸夢, 鹹齋積餘鏇醖繭憲淵夢 ~ 觸糧壓蓋繭遞範襯鹽範) 更多
NCT05552976 (SUCCESSOR-2, EHA2026)	临床3期	复发性多发性骨髓瘤	479	Mezigdomide 1.0 mg + Kd	襯蓋齋鑰艱廠構顧壓淵(選製獵夢獵鹹襯網鏇糧) = 範鏇憲遞選鏇壓壓齋鏇網範鹽築鑰膚醖願鏇積 (鹽壓觸夢積淵製窪鏇願 ) 更多	积极	2026-06-02
				Kd	襯蓋齋鑰艱廠構顧壓淵(選製獵夢獵鹹襯網鏇糧) = 壓窪廠鹹簾窪艱選範構網範鹽築鑰膚醖願鏇積 (鹽壓觸夢積淵製窪鏇願 ) 更多